EHA 2021 | MAIA: 5-year follow-up on DRd vs Rd in newly diagnosed myeloma
Saad Usmani, MD, MBBS, MBA, Levine Cancer Institute and Atrium Health, Charlotte, NC, shares an update on the MAIA study (NCT02252172), which is comparing daratumumab, lenalidomide and dexamethasone (DRd) to lenalidomide and dexamethasone (Rd) in transplant-ineligible patients with newly diagnosed multiple myeloma. Dr Usmani reports that with five years of follow-up the 60-month progression-free survival (PFS) rate is 52.5% for DRd, compared to 28.7% with Rd. Dr Usmani gives an overview of these results commenting on their implications. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript (edited for clarity)
So, the MAIA study is one of the larger contemporary clinical trials that have been done in newly diagnosed transplant-ineligible patients. Originally reported and published about two to three years ago. This study looked at the standard of care arm of Rd being given continuously compared to Dara-Rd on the experimental arm. And the study had originally read out positively in terms of its primary endpoint of PFS...
So, the MAIA study is one of the larger contemporary clinical trials that have been done in newly diagnosed transplant-ineligible patients. Originally reported and published about two to three years ago. This study looked at the standard of care arm of Rd being given continuously compared to Dara-Rd on the experimental arm. And the study had originally read out positively in terms of its primary endpoint of PFS. And now has a follow-up of about five years.
And these data being presented as a late breaking abstract by my colleague, Dr Thierry Facon, showing at the 16-month PFS at 52.5% for DRd and for Rd at 28.7%. So, the median PFS has not been reached for DRd, whereas it’s 34.4 months. Then, you know, PFS2 at the 16-month mark, very similar, kind of trend not reached for the DRd arm. And it’s 60.8% at the 60-month mark and 41.6% for the Rd arm of the study. And then, for the 16-month OS it’s 66.3% versus 53.1 on the Rd arm with a hazard ratio of 0.68, meaning statistical significant, with a p-value of 0.001.
And then, looking at the OS benefit, it was generally consistent across all patient groups. So, you know, interesting and exciting data. The PFS benefit obviously being confirmed, but OS at the 60-month mark, after follow-up, showing benefit in favor of the daratumumab containing arm of the study.
Read more...
Disclosures
Saad Usmani, MD, MBBS, MBA, has received research funding from Amgen, Array Biopharma, BMS, Celgene, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDX, Takeda; has received consulting fees from Abbvie, Amgen, BMS, Celgene, GSK, Genentech/Roche, Janssen, Karyopharm, Merck, Oncopeptides, Sanofi, Seattle Genetics, SkylineDx, Takeda; and has received speaking fees from Celgene, Janssen, Sanofi, Takeda.
